Debio 2511

Debio 2511 is a potential first-in-class bispecific antibody-drug conjugate (ADC) currently in the discovery stage of development by Debiopharm for oncology indications. The asset is built using Debiopharm's proprietary MultiLink™ technology, a versatile linker platform that enables the attachment of multiple payloads to an antibody, potentially achieving a high drug-to-antibody ratio (DAR) and improved therapeutic index. By targeting two distinct antigens simultaneously, Debio 2511 is designed to increase tumor selectivity and overcome potential resistance mechanisms associated with single-target therapies. While the specific biological targets and the nature of the cytotoxic payload remain undisclosed, the program represents a key part of Debiopharm's 'Trifecta' strategy for next-generation ADC development.